Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 13/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSB | P07858 | 8/20 | 0.50 |
| ▸ | CTSF | Q9UBX1 | 5/20 | 0.50 |
| ▸ | GRN | P28799 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14579995 | 1.00 | CTSL (0.53) | CTSLCTSKCTSSCTSBCTSF | |
| SCHEMBL5395043 | 0.98 | CTSL (0.52) | CTSLCTSKCTSSCTSBCTSF | |
| SCHEMBL13624180 | 0.92 | CTSL (0.52) | CTSLCTSKCTSSCTSBCTSF | |
| SCHEMBL2929115 | 0.88 | CTSL (0.55) | CTSLCTSKCTSSCTSBCTSF | |
| SCHEMBL3767672 | 0.88 | CTSL (0.55) | CTSLCTSKCTSSCTSBCTSF | |
| SCHEMBL2156721 | 0.88 | CTSL (0.55) | CTSLCTSKCTSSCTSBCTSF | |
| Potassium Ion SCHEMBL5200272 | 0.87 | CTSL (0.50) | CTSLCTSKCTSSCTSBCTSF | |
| SCHEMBL30219112 | 0.87 | CTSL (0.50) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL30219101 | 0.87 | CTSL (0.50) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL17585395 | 0.86 | CTSB (0.57) | CTSLCTSKCTSSCTSBCTSF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789379-B1 | DIASTEREOSELECTIVE REDUCTIVE AMINATION PROCESS | MERCK SHARP & DOHME (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-7183425-B2 | Diastereoselective reductive amination process | MERCK FROSST CANADA LTD. (CA) | 2007-02-27 | — | — | US | disclosed |
| US-7183425-B2 | Diastereoselective reductive amination process | MERCK FROSST CANADA LTD. (CA) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSL 24/4885CTSK 15/4885CTSS 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.